Evoke Pharma to Host Virtual Key Opinion Leader (KOL) Webinar on the Evolving Landscape of Gastroparesis
GIMOTI, Hospitalizations, and GLP-1 Medications
Michael Cline, DO., Medical Director Gastroparesis Clinic, Cleveland Clinic to present
SOLANA BEACH, Calif., April 17, 2024 (GLOBE NEWSWIRE) -- Evoke
Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI (metoclopramide) nasal
spray, announced it will host a virtual KOL and investor webinar on Wednesday, April 24 at 12:00 p.m. ET.
Moderated by Yale Jen, PhD, Senior Managing Director of Equity Research at Laidlaw Capital Markets, the event will feature Michael Cline, DO., Medical Director Gastroparesis Clinic, Cleveland Clinic and prescriber of GIMOTI will provide his expert opinion and insights on Evoke’s recently presented healthcare resource utilization data, patient experience with GIMOTI and the rising incidence of gastroparesis due to the increased use GLP-1 based medications.
Participation Details:
Date: April 24, 2024
Registration: Link Available on Evoke IR site under Events
Time: 12:00 p.m. ET
Lesen Sie auch
Investors are encouraged to email dboateng@dkbpartners.net prior to the event with queries.
About Evoke Pharma, Inc.
Evoke is a specialty pharmaceutical company focused primarily on the development of drugs to treat GI disorders and diseases. The company developed, commercialized and markets GIMOTI, a nasal spray formulation of metoclopramide, for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in adults.
Diabetic gastroparesis is a GI disorder affecting millions of patients worldwide, in which the stomach takes too long to empty its contents resulting in serious GI symptoms as well as other systemic complications. The gastric delay caused by gastroparesis can compromise absorption of orally administered medications. Prior to FDA approval to commercially market GIMOTI, metoclopramide was only available in oral and injectable formulations and remains the only drug currently approved in the United States to treat gastroparesis.
Visit www.EvokePharma.com for more information.
Follow GIMOTI on Facebook
Follow Evoke Pharma on Facebook
Follow Evoke Pharma on LinkedIn
Follow Evoke Pharma on Twitter
About Gimoti (metoclopramide) nasal spray
GIMOTI is indicated for the relief of symptoms in adults with acute and recurrent diabetic gastroparesis.